Capricor Therapeutics
CAPR
#5196
Rank
โ‚น159.19 B
Marketcap
โ‚น2,749
Share price
-2.40%
Change (1 day)
207.88%
Change (1 year)

Revenue for Capricor Therapeutics (CAPR)

Revenue in 2025 (TTM): N/A

a decrease over the revenue in the year 2024 that were of โ‚น1.91 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Capricor Therapeutics from 2009 to 2025

Annual revenue

Year Revenue Change
2025 N/A-100%
2024 โ‚น1.91 B-8.85%
2023 โ‚น2.09 B892.75%
2022 โ‚น0.21 B1058.29%
2021 โ‚น18.22 M-19.66%
2020 โ‚น22.68 M-68.34%
2019 โ‚น71.66 M-38.67%
2018 โ‚น0.11 B-16.45%
2017 โ‚น0.13 B-35.48%
2016 โ‚น0.21 B-13.61%
2015 โ‚น0.25 B-4.98%
2014 โ‚น0.26 B
2013 N/A-100%
2012 โ‚น10.7 M-85.06%
2011 โ‚น71.65 M
2010 N/A
2009 N/A

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Johnson & Johnson
JNJ
โ‚น9.175 TN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
โ‚น295.41 BN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Cytokinetics
CYTK
โ‚น10.07 BN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
โ‚น0.14 BN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
โ‚น0.84 BN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Eterna Therapeutics
ERNA
โ‚น0.09 MN/A๐Ÿ‡บ๐Ÿ‡ธ USA